Skip to main content
. 2017 Jun 21;13(9):2048–2057. doi: 10.1080/21645515.2017.1337615

Figure 1.

Figure 1.

Subject disposition summary. Altogether 120 participants were enrolled and each group of 29 to 31 subjects was immunized with TIV1, ADV, IDV or TIV2 influenza vaccines. TIV1 = subunit vaccine; ADV = subunit vaccine with MF59 adjuvant; TIV2 = split-virus vaccine; IDV = split-virus vaccine given intradermally.